Fosun Pharma: Signs Licensing Agreement with NewCo to Obtain Rights to Develop AR1001 Drug in China

Fosun Pharma announced that its controlling subsidiary, Fosun Pharmaceutical Industry, has signed a licensing agreement with Nucor to obtain the development, registration, production, and commercialization rights of the drug AR1001 in the agreed-upon licensed area and field. According to the agreement, Fosun Pharmaceutical Industry will pay up to a total of 150 million yuan in initial payment and regulatory milestone payments. As of the date of this announcement, there is still no drug approved for marketing globally with the same target for the treatment of Alzheimer's disease.